EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise
Standard
EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise. / Westphal, Manfred; Maire, Cecile L; Lamszus, Katrin.
in: CNS DRUGS, Jahrgang 31, Nr. 9, 09.2017, S. 723-735.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise
AU - Westphal, Manfred
AU - Maire, Cecile L
AU - Lamszus, Katrin
PY - 2017/9
Y1 - 2017/9
N2 - The receptor for epidermal growth factor (EGFR) is a prime target for cancer therapy across a broad variety of tumor types. As it is a tyrosine kinase, small molecule tyrosine kinase inhibitors (TKIs) targeting signal transduction, as well as monoclonal antibodies against the EGFR, have been investigated as anti-tumor agents. However, despite the long-known enigmatic EGFR gene amplification and protein overexpression in glioblastoma, the most aggressive intrinsic human brain tumor, the potential of EGFR as a target for this tumor type has been unfulfilled. This review analyses the attempts to use TKIs and monoclonal antibodies against glioblastoma, with special consideration given to immunological approaches, the use of EGFR as a docking molecule for conjugates with toxins, T-cells, oncolytic viruses, exosomes and nanoparticles. Drug delivery issues associated with therapies for intracerebral diseases, with specific emphasis on convection enhanced delivery, are also discussed.
AB - The receptor for epidermal growth factor (EGFR) is a prime target for cancer therapy across a broad variety of tumor types. As it is a tyrosine kinase, small molecule tyrosine kinase inhibitors (TKIs) targeting signal transduction, as well as monoclonal antibodies against the EGFR, have been investigated as anti-tumor agents. However, despite the long-known enigmatic EGFR gene amplification and protein overexpression in glioblastoma, the most aggressive intrinsic human brain tumor, the potential of EGFR as a target for this tumor type has been unfulfilled. This review analyses the attempts to use TKIs and monoclonal antibodies against glioblastoma, with special consideration given to immunological approaches, the use of EGFR as a docking molecule for conjugates with toxins, T-cells, oncolytic viruses, exosomes and nanoparticles. Drug delivery issues associated with therapies for intracerebral diseases, with specific emphasis on convection enhanced delivery, are also discussed.
KW - Journal Article
U2 - 10.1007/s40263-017-0456-6
DO - 10.1007/s40263-017-0456-6
M3 - SCORING: Journal article
C2 - 28791656
VL - 31
SP - 723
EP - 735
JO - CNS DRUGS
JF - CNS DRUGS
SN - 1172-7047
IS - 9
ER -
